Kan AI forudsige individuel kræftrecidivrisiko ved hjælp af tumors genetisk sekventering ?

Kræftrecidiv afhænger af et komplekst samspil mellem genetiske mutationer, tumorens mikro miljø og behandlingsrespons. Personlig medicin sigter mod at forudsige recidivrisiko ved at analysere tumorgenomik, men integrationen af store datamængder forbliver udfordrende for menneskelige klinikere. AI kunne accelerere denne proces ved at identificere mønstre forbundet med tilbagefald i højdimensionelle data.

Background

Cancer relapse is shaped by interactions among somatic mutations, the tumor microenvironment, systemic immunity, and therapeutic selection pressures. Personalized oncology seeks to quantify recurrence risk from tumor genomics, but integrating high-dimensional genomic, epigenomic, transcriptomic, and clinical data within a single workflow remains non-trivial for human interpreters.

AI-driven pipelines now fuse whole-exome or whole-transcriptome tumor sequencing with clinical covariates to generate individualized recurrence-risk estimates. Commercial gene-expression assays such as Oncotype DX AR-V7 (prostate cancer) and FoundationOne Hemo (hematologic malignancies) and the breast-cancer panel Oncotype DX Breast Recurrence Score have received regulatory clearance and provide prognostic signatures correlated with distant recurrence and survival endpoints. Deep-learning models trained on TCGA cohorts report AUCs of ≈0.75–0.85 for predicting relapse across several tumor types, outperforming traditional histopathology-based staging in validation splits. Regulatory-cleared tools are currently labeled for prognosis (i.e., outcome prediction) rather than therapy selection (predictive use), and their performance in non-academic, multi-institution cohorts is still being evaluated. Reference: Nature Medicine, enriched May 12 2026.